JP2012524059A - ミトコンドリア疾患の治療用化合物 - Google Patents

ミトコンドリア疾患の治療用化合物 Download PDF

Info

Publication number
JP2012524059A
JP2012524059A JP2012505253A JP2012505253A JP2012524059A JP 2012524059 A JP2012524059 A JP 2012524059A JP 2012505253 A JP2012505253 A JP 2012505253A JP 2012505253 A JP2012505253 A JP 2012505253A JP 2012524059 A JP2012524059 A JP 2012524059A
Authority
JP
Japan
Prior art keywords
atom
compound
carbon atoms
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012505253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524059A5 (enExample
Inventor
ブロンデル，マルク
クプラン，エロディー
ラゴ，ジャン−ポール ディ
ドゾンヌ，ダニエル
パラディノ，マイケル
チェロット，アリシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2012524059A publication Critical patent/JP2012524059A/ja
Publication of JP2012524059A5 publication Critical patent/JP2012524059A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Tents Or Canopies (AREA)
JP2012505253A 2009-04-17 2010-04-15 ミトコンドリア疾患の治療用化合物 Pending JP2012524059A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290288A EP2243476A1 (en) 2009-04-17 2009-04-17 Compounds for the treatment of mitochondrial diseases
EP09290288.1 2009-04-17
PCT/IB2010/001006 WO2010119344A1 (en) 2009-04-17 2010-04-15 Compounds for the treatment of mitochondrial diseases

Publications (2)

Publication Number Publication Date
JP2012524059A true JP2012524059A (ja) 2012-10-11
JP2012524059A5 JP2012524059A5 (enExample) 2013-05-30

Family

ID=40972893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505253A Pending JP2012524059A (ja) 2009-04-17 2010-04-15 ミトコンドリア疾患の治療用化合物

Country Status (5)

Country Link
US (2) US20120329834A1 (enExample)
EP (2) EP2243476A1 (enExample)
JP (1) JP2012524059A (enExample)
CA (1) CA2758855A1 (enExample)
WO (1) WO2010119344A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088113A1 (en) * 2010-01-12 2011-07-21 Cabreeco Companies Llc Movable enclosure
US20110308173A1 (en) * 2009-09-04 2011-12-22 Forsland Kent H Movable building structure
US9458621B2 (en) * 2012-11-28 2016-10-04 Expanding Buildings Pty Ltd Transportable and expandable building structure
CA2849567C (en) * 2013-04-18 2016-05-24 James Bert Farmer Portable building
US9549942B2 (en) * 2013-07-15 2017-01-24 Research & Business Foundation Sungkyunkwan University Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins
FR3029113A1 (fr) * 2014-12-02 2016-06-03 Univ Paris-Sud Composes pour le traitement des maladies mitochondriales
JP6404395B1 (ja) * 2017-03-31 2018-10-10 Ｊｓｃ株式会社 アリーナ及びアリーナの施工方法
CN118923413B (zh) * 2024-08-12 2025-05-30 中科绿控科技有限公司 一种蔬菜种植用的智能防虫设备

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL45585C (enExample) 1936-05-28 1900-01-01
US2170111A (en) 1936-05-28 1939-08-22 Rohm & Haas Manufacture of amines
US2229024A (en) 1939-05-23 1941-01-21 Rohm & Haas Aromatic ether of polyalkoxyalkylalkylene polyamines and process for obtaining them
US2684924A (en) 1951-02-05 1954-07-27 Ici Ltd Nu-chlorophenyldiguanidino compounds
US2745826A (en) 1953-12-16 1956-05-15 Olin Mathieson Process of preparing thiourea complexes
US3766691A (en) * 1971-12-02 1973-10-23 G Ray Convertible pool enclosure
US4280306A (en) * 1979-06-04 1981-07-28 Vojin Milinic Convertible enclosure for buildings and areas
US4478268B1 (en) * 1980-12-29 1991-04-23 Door structure
CA1260025A (en) * 1985-11-14 1989-09-26 M & I Door Systems Limited Apparatus for opening and closing industrial door
US4974658A (en) * 1989-02-22 1990-12-04 Komatsu Denki Sangyo Kabushiki Kaisha Sheet shutter
US5038517A (en) * 1989-05-19 1991-08-13 Talbott Gene B Greenhouse construction
US5484007A (en) * 1990-05-11 1996-01-16 Rejc; Gabrijel Vertical lift gate with strip cladding in guideways
DE4015216A1 (de) * 1990-05-11 1991-11-14 Efaflex Transport Lager Abschlusselement fuer eine oeffnung
US4984399A (en) * 1990-06-25 1991-01-15 Taylor Gary L Automobile enclosure
US5139074A (en) * 1991-04-03 1992-08-18 Kelley Company Inc. Industrial door having flexible and releasable beam
US5123474A (en) * 1991-05-13 1992-06-23 Smith Richard C Roll-up closure device
US5392836A (en) * 1992-06-23 1995-02-28 Rite Hite Corporation Door assembly
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
US5601134A (en) * 1995-03-23 1997-02-11 Rite-Hite Corporation Retainer assembly for roll-up door
US5765622A (en) * 1996-11-08 1998-06-16 Thruways Doorsystems Inc. Vertically moveable flexible door with releasable bottom bar
WO1999005381A2 (en) * 1997-07-25 1999-02-04 Rytec Corporation Roll-up overhead door for sanitary applications
US6098698A (en) * 1998-12-11 2000-08-08 King-Darr; Carol L. Garage door opening screen enclosure
SE9903760D0 (sv) * 1999-10-18 1999-10-18 Astra Ab New compounds
US6296039B1 (en) * 2000-03-08 2001-10-02 Wayne-Dalton Corporation Apparatus and method for windlocking a building opening
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US7240715B2 (en) * 2003-12-24 2007-07-10 Hunter Douglas Inc. Limit stop for coverings for architectural openings
US20070037800A1 (en) * 2005-06-23 2007-02-15 Envivo Pharmaceuticals, Inc. Method of treating neurological disorders using clotrimazole and derivatives thereof
US20070208086A1 (en) * 2006-02-15 2007-09-06 The Regents Of The University Of California Ubiquinone analogs and methods of use
FR2900660B1 (fr) 2006-05-03 2008-07-11 Univ Victor Segalen Bordeaux 2 Modelisation chez la levure des mutations du gene mitochondrial atp6 responsables du syndrome narp chez l'homme et ses applications pour le criblage de medicaments

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5012011607; ＲＯＴＡ　Ｍ　Ｔ: 'ＲＥＤＵＣＴＩＯＮ　ＯＦ　ＯＲＡＬ　ＡＣＥＴＡＬＤＥＨＹＤＥ　ＬＥＶＥＬＳ　ＵＳＩＮＧ　Ａ　ＣＯＮＴＲＯＬＬＥＤ-ＲＥＬＥＡＳＥ　ＣＨＬＯＲＨＥＸＩＤＩＮＥ　ＣＨＩＰ　以下備考' ＭＥＤＩＣＡＬ　ＨＹＰＯＴＨＥＳＥＳ Ｖ６０　Ｎ６, 200306, Ｐ８５６-８５８ *
JPN6014017892; ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＥＮＤＯＤＯＮＴＩＣ　ＪＯＵＲＮＡＬ ＶＯＬ．４０, 2007, Ｐ．８３７-８４４ *
JPN6014017893; ＨＵＭＡＮ　ＭＯＬＥＣＵＬＡＲ　ＧＥＮＥＴＩＣＳ ＶＯＬ．１０，　ＮＯ．１１, 2001, Ｐ．１２２１-１２２８ *
JPN6014017894; ＨＵＭＡＮ　ＭＯＬＥＣＵＬＡＲ　ＧＥＮＥＴＩＣＳ ＶＯＬ．１３，　ＮＯ．８, 2004, Ｐ．８６９-８７９ *

Also Published As

Publication number Publication date
EP2419094A1 (en) 2012-02-22
WO2010119344A1 (en) 2010-10-21
CA2758855A1 (en) 2010-10-21
US20120090250A1 (en) 2012-04-19
EP2419094B1 (en) 2016-06-08
US20120329834A1 (en) 2012-12-27
EP2243476A1 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
JP2012524059A (ja) ミトコンドリア疾患の治療用化合物
Wang et al. The mitophagy pathway and its implications in human diseases
Obergasteiger et al. A new hypothesis for Parkinson’s disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics
ES2685947T3 (es) Agentes antienvejecimiento
JP2005170955A (ja) ビス−スタウロスポリンおよびＫ−２５２ａ誘導体
ES2661009T3 (es) Succinatos protegidos para mejorar la producción de ATP mitocondrial
US20190183915A1 (en) Use of aminoglycoside analogs in the treatment of rett syndrome
EP2605769B1 (en) Benzoquinone derivatives for the treatment of mitchondrial eye diseases
CN114478451B (zh) 6-(羟基苄氧基)苯酞曼尼希碱类化合物、其制备方法和用途
US20100273769A1 (en) Composition and method for the treatment of parkinson's disease
US10519157B2 (en) Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
CA3204205A1 (en) Lectin protein for treatment and prevention of neurodegenerative diseases
CN117143028B (zh) 一类羟苯基哒嗪曼尼希碱类化合物及其制备方法和用途
KR20220071285A (ko) 미토콘드리아 기능 향상 및 미토콘드리아 질환 치료를 위한 화합물의 신규 치료적 용도
ITRM960180A1 (it) Bis alcanoil esteri della carnitina ad attivita' antibatterica, anti= micotica ed antiprotozoaria.
US10639287B2 (en) Compounds for the treatment of mitochondrial diseases
US7074938B2 (en) Method for the synthesis of soritin compounds
NO334797B1 (no) Anvendelse av tiazolderivater for fremstilling av et medikament for beskyttelse av mitokondrier
US11820762B2 (en) Compounds as potential therapeutic agents targeting various neurodegenerative diseases
AU2023302582A1 (en) Use of ebselen or one of the derivatives thereof to treat mitochondrial pathologies or dysfunctions
AU2024256829A1 (en) Combination of metformin and rapamycin for treating neurological, muscular, and proliferative disorders
EP4440569A1 (en) Derivatives of nifuroxazide for use in the treatment of mitochondrial disorders and neurodegenerative diseases
Kidoa et al. Drug development for human African trypanosomiasis targeting its cyanide-insensitive respiration
Maheshwari et al. Nigrospora sphaerica Products from the Flowering Dogwood Exhibit Antitumorigenic Effects via down-regulation of the Translational Regulator, Ribosomal S6 Protein
Houštěk et al. Genetic disorders of mitochondrial ATP synthase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140718

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140901

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150120